Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Brian W Labadie,1 David S Morris,2 Alan H Bryce,3 Robert Given,4,5 Jingsong Zhang,6 Wassim Abida,7 Simon Chowdhury,8,9 Akash Patnaik1 1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA; 2Urology Associates, P.C., Nashville, TN, USA; 3Hematology and Medic...
Main Authors: | Labadie BW, Morris DS, Bryce AH, Given R, Zhang J, Abida W, Chowdhury S, Patnaik A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-02-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/guidelines-for-management-of-treatment-emergent-adverse-events-during--peer-reviewed-fulltext-article-CMAR |
Similar Items
-
Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis
by: Nicholas Adrianto, et al.
Published: (2024-09-01) -
PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape
by: Ashaar Al-Akhras, et al.
Published: (2024-01-01) -
Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages
by: Cassandra L. R. van Doorn, et al.
Published: (2021-11-01) -
Successful case of olaparib treatment for castration-resistant prostate cancer with multiple DNA repair gene mutations: Use of comprehensive genome profiling for treatment-refractory cases
by: Yukiyoshi Hirayama, et al.
Published: (2022-11-01) -
Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
by: Xiangyu Chen, et al.
Published: (2023-10-01)